Precision medicine in resource-limited settings: the central role of pathology
DOI:
https://doi.org/10.59736/IJP.24.02.1048Keywords:
Breast Cancer, Immunohistochemistry, Hormone Receptors, HER2Abstract
Precision medicine (also known as individualized or personalized medicine) is a novel approach that integrates genetic, environmental, and lifestyle data to drive medical care decisions. It aims to give more precise approaches to illness prevention, diagnosis, and treatment.(1) In oncology, precision medicine is based on the premise that malignancies are not all the same, and people may respond differently to therapies depending on their genetic, environmental, and lifestyle variables.(2) In high-income countries, precision medicine is frequently associated with genomics and molecular profiling. The most common cancers (lung, breast, colorectal, prostate, stomach) all require histopathological diagnosis and immunohistochemistry (IHC) (e.g. ER/PR/HER2 in breast cancer) as part of the WHO Essential Diagnostics framework. Therefore, precision medicine does not have to include expensive whole-genome sequencing. Accurate pathology, basic immunohistochemistry, morphology, and low-cost molecular diagnostics can all provide precision treatment.
References
Delpierre C, Lefèvre T. Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol. 2023; 8:1112159.
Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024; 25:8140.
Radich JP, Briercheck E, Chiu DT, Menon MP, Torra OS, Yeung CCS, et al. Precision Medicine in Low- and Middle-Income Countries. Annu Rev Pathol. 2022; 17:387–402.
Lancet T. GLOBOCAN 2018: counting the toll of cancer. The Lancet. 2018 ;392:985.
Ramos-Vara JA. Principles and Methods of Immunohistochemistry. Methods Mol Biol. 2017;1641:115–28.
Thanasan S, Sukhakul K, Chitpakdee S, Kitkumthorn N. Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer. Asian Pac J Cancer Prev. 2023;24:4321–7.
Gilani A, Mushtaq N, Shakir M, Altaf A, Siddiq Z, Bouffet E, et al. Pediatric neuropathology practice in a low- and middle-income country: capacity building through institutional twinning. Front Oncol. 2024;14:1328374.
Zehra T, Ahmed Z, Shams M. Current Practice Of Histopathology In Pakistan: Difficulties, Challenges, And Solutions. J Pak Med Assoc. 2023;73:1488–90.
Bagchi A, Madaj Z, Engel KB, Guan P, Rohrer DC, Valley DR, et al. Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry. J Histochem Cytochem. 2021;69:297–320.
Saj F, Nag S, Nair N, Sirohi B. Management of BRCA-associated breast cancer patients in low and middle-income countries: a review. Ecancermedicalscience. 2024 18:1744.
Published
Issue
Section
License
Copyright (c) 2026 Ariba Asif
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
